---

Chief Scientific Officer, Alchemab Therapeutics

Prior to joining Alchemab, Jane Osbourn served as vice president of R&D at MedImmune, where she contributed to the development of antibody phage display technology, authored key publications and patents, and worked on the discovery and development of a number of marketed antibody therapies including adalimumab and durvalumab.

Today, she is also chair of the Cambridge-based cell therapy company Mogrify and a member of the Crick Translational Advisory Group. She has served as a Member of the UK Medical Research Council Industry Grant Award Assessment Panel, and, from 2015–2019, served as Chair of the Board of Directors of the UK BioIndustry Association.

She was awarded an Order of the British Empire and Scrip’s Lifetime Achievement Award in 2019 for services to drug discovery, development and biotechnology. 

“The generosity of patients in giving their insights, time, clinical samples, enabling assessments, and being prepared to try and help others to improve health, even if that comes with risk and inconvenience, has always inspired me.”